Sundarbar Vaidyakhana is set to produce Ayurvedic medicines such as Shilajit and Mimiyal this year following the World Health Organization’s Good Manufacturing Practice (GMP) standards. Currently, Vaidyakhana is manufacturing 103 types of medicines this fiscal year, surpassing its initial target, stated Executive Director Dr. Pradeep KC. Over the past five years, the institution has shifted from losses to profitability by increasing medicine production, utilizing 55,000 kilograms of raw materials annually. Kathmandu, 16 April.
Sundarbar Vaidyakhana is preparing to align its Ayurvedic medicine production with the WHO’s GMP standards to ensure high-quality manufacturing practices. Executive Director Dr. Pradeep KC confirmed that medicines including Shilajit and Mimiyal will soon be produced under GMP guidelines. From the next fiscal year, production of powders and tablets will also comply with these standards.
Since assuming leadership, Director KC highlighted a significant increase in medicine production at Vaidyakhana. Currently, 103 different types of medicines are being produced. “Our target for this fiscal year was set at 84 types, yet we are producing 103 types of medicines,” he explained. “With collaborative efforts, we have expanded production capacity.” In fiscal year 2081/82, the goal was to produce 77 types of medicines, but only 40 types were made. In previous years, production ranged from 14 to 25 types annually. Dr. KC also noted that the institution, which had been operating at a loss for five years, has now achieved profitability through increased production. Currently, the facility processes 55,000 kilograms of raw materials per year and has executed 85 work contracts out of 101 procurement orders received so far.
